RÉSUMÉ
Purpose: To investigate the therapeutic effects of eye drops, namely, timolol maleate, a ß-adrenergic receptor antagonist, and latanoprost, a prostaglandin F2α analog, on retinal edema in a murine retinal vein occlusion (RVO) model. Methods: An RVO model was established using laser-induced RVO in mice, which were administered timolol maleate and latanoprost eye drops several times after venous occlusion. Subsequently, the thickness of the inner nuclear layer (INL) and the expression levels of such genes as Vegf and Atf4, which are stress markers of the endoplasmic reticulum, were examined. Primary human cultured retinal microvascular endothelial cells (HRMECs) were treated with timolol under hypoxic conditions, after which the gene expression pattern was investigated. Importantly, an integrated stress response inhibitor (ISRIB) was used in the RVO model, he known ISRIB, which suppresses the expression of ATF4 in retinal edema. Results: Increased INL thickness was suppressed by timolol eye drops, as were the expressions of Vegf and Atf4, in the RVO model. However, latanoprost eye drops did not induce any change in INL thickness. In HRMECs, hypoxic stress and serum deprivation increased the Vegf and Atf4 expressions; in response, treatment with timolol suppressed the Vegf expression. Furthermore, the ISRIB decreased the Vegf expression pattern and edema formation, which are associated with RVO. Conclusions: These results indicate that timolol eye drops may be a potential option for RVO treatment.
Sujet(s)
Oedème papillaire , Occlusion veineuse rétinienne , Mâle , Humains , Souris , Animaux , Timolol/pharmacologie , Timolol/usage thérapeutique , Timolol/métabolisme , Occlusion veineuse rétinienne/complications , Occlusion veineuse rétinienne/traitement médicamenteux , Occlusion veineuse rétinienne/métabolisme , Solutions ophtalmiques/usage thérapeutique , Latanoprost/pharmacologie , Latanoprost/métabolisme , Latanoprost/usage thérapeutique , Oedème papillaire/traitement médicamenteux , Cellules endothéliales/métabolisme , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Oedème/complicationsRÉSUMÉ
Drug metabolite profiling utilizes liquid chromatography with tandem mass spectrometry (LC/MS/MS) to acquire ample information for metabolite identification and structural elucidation. However, there are still challenges in detecting and characterizing all potential metabolites that can be masked by a high biological background, especially the unknown and uncommon ones. In this work, a novel metabolite profiling workflow was established on a platform using a state-of-the-art tribrid high-resolution mass spectrometry (HRMS) system. Primarily, an instrumental method was developed based on the novel design of the tribrid system that facilitates in-depth MSn scans with two fragmentation devices. Additionally, different advanced data acquisition techniques were assessed and compared, and automatic background exclusion and deep-scan approaches were adopted to promote assay efficiency and metabolite coverage. Finally, different data-analysis techniques were explored to fully extract metabolite data from the information-rich MS/MS data sets. Overall, a workflow combining tribrid mass spectrometry and advanced acquisition methodology has been developed for metabolite characterization in drug discovery and development. It maximizes the tribrid HRMS platform's utility and enhances the coverage, efficiency, quality, and speed of metabolite profiling assays.
Sujet(s)
Traitement automatique des données/méthodes , Préparations pharmaceutiques/métabolisme , Spectrométrie de masse en tandem/méthodes , Acétates/métabolisme , Acétates/pharmacocinétique , Buspirone/métabolisme , Buspirone/pharmacocinétique , Chromatographie en phase liquide/méthodes , Cyclopropanes/métabolisme , Cyclopropanes/pharmacocinétique , Fouille de données , Conception d'appareillage , Métabolomique/méthodes , Microsomes du foie/effets des médicaments et des substances chimiques , Préparations pharmaceutiques/analyse , Quinoléines/métabolisme , Quinoléines/pharmacocinétique , Sulfures/métabolisme , Sulfures/pharmacocinétique , Spectrométrie de masse en tandem/instrumentation , Ticlopidine/métabolisme , Ticlopidine/pharmacocinétique , Timolol/métabolisme , Timolol/pharmacocinétique , Flux de travauxRÉSUMÉ
In recent years, with the aging of the population and the frequent use of electronic devices, many eye diseases have shown a linear upward trend, such as dry eye disease, glaucoma, cataract, age-related macular degeneration, and diabetic retinopathy. These diseases are often chronic and difficult to cure. Based on the structure and barrier of the human eye, this review describes the pathogenesis and treatments of several intractable eye diseases and summarizes the advanced ocular drug delivery systems to provide new treatment ideas for these diseases. Finally, we also look forward to the prospect of RNAi therapy in the treatment of eye diseases.
Sujet(s)
Systèmes de délivrance de médicaments/méthodes , Maladies de l'oeil/traitement médicamenteux , Maladies de l'oeil/métabolisme , Antagonistes bêta-adrénergiques/administration et posologie , Antagonistes bêta-adrénergiques/métabolisme , Antihypertenseurs/administration et posologie , Antihypertenseurs/métabolisme , Cataracte/diagnostic , Cataracte/traitement médicamenteux , Cataracte/métabolisme , Rétinopathie diabétique/diagnostic , Rétinopathie diabétique/traitement médicamenteux , Rétinopathie diabétique/métabolisme , Syndromes de l'oeil sec/diagnostic , Syndromes de l'oeil sec/traitement médicamenteux , Syndromes de l'oeil sec/métabolisme , Maladies de l'oeil/diagnostic , Glaucome/diagnostic , Glaucome/traitement médicamenteux , Glaucome/métabolisme , Humains , Latanoprost/administration et posologie , Latanoprost/métabolisme , Dégénérescence maculaire/traitement médicamenteux , Dégénérescence maculaire/épidémiologie , Dégénérescence maculaire/physiopathologie , Photosensibilisants/administration et posologie , Photosensibilisants/métabolisme , Timolol/administration et posologie , Timolol/métabolisme , Résultat thérapeutique , Vertéporfine/administration et posologie , Vertéporfine/métabolismeRÉSUMÉ
A fixed combination of bimatoprost/timolol eye drop solution is used to manage the elevated intra-ocular pressure in glaucoma patients, including individuals whose condition is poorly controlled by monotherapy. Eye drop solutions are generally given in high dose, due to poor ocular bioavailability. The high ocular dose of bimatoprost and timolol lead to hyperaemia and systemic cardiac side effects respectively. Here, we introduce multiple implant-laden contact lenses (IM) to passively deliver timolol, bimatoprost and hyaluronic acid at therapeutically relevant doses without high burst release. The drug-loaded implants were individually implanted in the outer periphery of the silicone contact lenses. Atomic force microscopy showed the smooth surface of the implant contact lens, as the implants were inside the contact lens matrix. The implant lens (IM) showed major loss of drugs [timolol = 60.60%, bimatoprost = 61.75% and HA = 46.03%] during the monomer extraction and wet sterilization, while the option of dry radiation sterilization (IM-R lens) and hydration for 24 h prior to use showed relatively lower loss of drugs [timolol = 16.87%, bimatoprost = 47.95% and HA = 24.41%]. The in-vitro drugs release data of IM-R lens, showed sustained release for 72 h, with low burst release in comparison to the soaked (SM) and direct drug-laden contact lenses (DL). The in vivo drug release data in the rabbit tear fluid showed sustained release using IM-R lens in comparison to the SM lens and eye drop therapy. The burst release with the IM-R lens was many folds reduced, which could bypass the side effects associated with multiple eye drop therapy. The in vivo pharmacodynamic study in the rabbit model showed peak and valley profile with multiple eye drop therapy, while IM-R lens showed prolong reduction in intra ocular pressure (IOP) for 120 h. The study demonstrates the application of implantation technology to deliver multiple drug through contact lenses to treat glaucoma.
Sujet(s)
Bimatoprost/métabolisme , Lentilles de contact , Vecteurs de médicaments/composition chimique , Silicone/composition chimique , Timolol/métabolisme , Animaux , Bimatoprost/administration et posologie , Bimatoprost/composition chimique , Implant pharmaceutique/composition chimique , Libération de médicament , Acide hyaluronique/administration et posologie , Acide hyaluronique/composition chimique , Acide hyaluronique/métabolisme , Pression intraoculaire , Lapins , Propriétés de surface , Timolol/administration et posologie , Timolol/composition chimiqueRÉSUMÉ
There is great potential to improve drug delivery through the use of in-situ gelling delivery systems. Here we demonstrate a technique capable of measuring changes in rheology (gelation and/or dissolution) of in-situ gelling delivery systems on contact with physiological fluid, while simultaneously analysing drug release. An ocular in-situ gelling formulation (gellan and timolol maleate) and an in-situ gelling oral liquid (alginate and metronidazole) were used as exemplar formulations. The method allowed profiling of increasing gellan concentration resulting in a reduction of timolol maleate released into simulated lacrimal fluid. When alginate was used as an in-situ gelling oral formulation there was a rapid increase in G' on contact with simulated gastric fluid. When this was changed to simulated intestinal fluid, drug release rate increased rapidly, coinciding with alginate gel dissolution. This work highlights the potential of this technology as a tool in development and optimisation of these increasingly popular delivery systems.
Sujet(s)
Vecteurs de médicaments/composition chimique , Gels/composition chimique , Métronidazole/composition chimique , Timolol/composition chimique , Alginates/composition chimique , Chimie pharmaceutique , Libération de médicament , Métronidazole/métabolisme , Solutions ophtalmiques/composition chimique , Solutions ophtalmiques/métabolisme , Polyosides bactériens/composition chimique , Rhéologie , Timolol/métabolisme , ViscositéRÉSUMÉ
The objective of this study was to systematically investigate the effects of surface active ophthalmic excipients on the corneal permeation of ophthalmic drugs using in vitro (HCE-T cell-based model) and ex vivo (freshly excised porcine cornea) models. The permeation of four ophthalmic drugs (i.e., timolol maleate, chloramphenicol, diclofenac sodium and dexamethasone) across in vitro and ex vivo corneal models was evaluated in the absence and presence of four commonly used surface active ophthalmic excipients (i.e., Polysorbate 80, Tyloxapol, Cremophor® EL and Pluronic® F68). The concentration and self-aggregation-dependent effects of surface active ophthalmic excipients on ophthalmic drug permeability were studied from the concentration region where only dissolved monomer molecules of surface active ophthalmic excipients exist, as well as the concentration region in which aggregates of variable size and dispersion are spontaneously formed. Neither the surface active ophthalmic excipients nor the ophthalmic drugs at all concentrations that were tested significantly affected the barrier properties of both corneal models, as assessed by transepithelial electrical resistance (TEER) monitoring during the permeability experiments. The lowest concentration of all investigated surface active ophthalmic excipients did not significantly affect the ophthalmic drug permeability across both of the corneal models that were used. For three ophthalmic drugs (i.e., chloramphenicol, diclofenac sodium and dexamethasone), depressed in vitro and ex vivo permeability were observed in the concentration range of either Polysorbate 80, Tyloxapol, Cremophor® EL or Pluronic® F68, at which self-aggregation is detected. The effect was the most pronounced for Cremophor® EL (1 and 2%, w/V) and was the least pronounced for Pluronic® F68 (1%, w/V). However, all surface active ophthalmic excipients over the entire concentration range that was tested did not significantly affect the in vitro and ex vivo permeability of timolol maleate, which is the most hydrophilic ophthalmic drug that was investigated. The results of the dynamic light scattering measurements point to the association of ophthalmic drugs with self-aggregates of surface active ophthalmic excipients as the potential mechanism of the observed permeability-depressing effect of surface active ophthalmic excipients. A strong and statistically significant correlation was observed between in vitro and ex vivo permeability of ophthalmic drugs in the presence of surface active ophthalmic excipients, which indicates that the observed permeability-altering effects of surface active ophthalmic excipients were comparable and were mediated by the same mechanism in both corneal models.
Sujet(s)
Épithélium antérieur de la cornée/effets des médicaments et des substances chimiques , Excipients/administration et posologie , Absorption oculaire/effets des médicaments et des substances chimiques , Préparations pharmaceutiques/administration et posologie , Tensioactifs/administration et posologie , Administration par voie ophtalmique , Animaux , Biopharmacie/méthodes , Lignée cellulaire , Chloramphénicol/administration et posologie , Chloramphénicol/métabolisme , Dexaméthasone/administration et posologie , Dexaméthasone/métabolisme , Diclofenac/administration et posologie , Diclofenac/métabolisme , Préparation de médicament , Diffusion dynamique de la lumière , Impédance électrique , Épithélium antérieur de la cornée/métabolisme , Excipients/composition chimique , Femelle , Glycérol/administration et posologie , Glycérol/analogues et dérivés , Humains , Mâle , Solutions ophtalmiques , Perméabilité , Préparations pharmaceutiques/composition chimique , Préparations pharmaceutiques/métabolisme , Poloxamère/administration et posologie , Polyéthylène glycols/administration et posologie , Polysorbates/administration et posologie , Tensioactifs/composition chimique , Sus scrofa , Technologie pharmaceutique/méthodes , Facteurs temps , Timolol/administration et posologie , Timolol/métabolismeRÉSUMÉ
Advances in nanotechnology have enabled solutions for challenging drug delivery targets. While the eye presents numerous emerging opportunities for delivery, analysis and sensing; issues persist for conventional applications. This includes liquid phase formulation localisation on the ocular surface once administered as formulated eye-drops; with the vast majority of dosage (>90%) escaping from the administered site due to tear production and various drainage mechanisms. The work presented here demonstrates a single needle electrohydrodynamic (EHD) engineering process to nano-coat (as an on demand and controllable fiber depositing method) the surface of multiple contact lenses rendering formulations to be stationary on the lens and at the bio-interface. The coating process was operational based on ejected droplet charge and glaucoma drug timolol maleate (TM) was used to demonstrate surface coating optimisation, bio-surface permeation properties (flux, using a bovine model) and various kinetic models thereafter. Polymers PVP, PNIPAM and PVP:PNIPAM (50:50%w/w) were used to encapsulate the active. Nano-fibrous and particulate samples were characterised using SEM, FTIR, DSC and TGA to confirm structural and thermal stability of surface coated formulations. More than 52% of nano-structured coatings (for all formulations) were <200nm in diameter. In vitro studies show coatings to exhibit biphasic release profiles; an initial burst release followed by sustained release; with TM-loaded PNIPAM coating releasing most drug after 24h (89.8%). Kinetic modelling (Higuchi, Korsmeyer-Peppas) was indicative of quasi-Fickian diffusion whilst biological evaluation demonstrates adequate ocular tolerability. Results from permeation studies indicate coated lenses are ideal to reduce dosing regimen, which in turn will reduce systemic drug absorption. Florescent microscopy demonstrated probe and probe embedded coating behaviour from lens surface in vitro. The multiple lens surface coating method demonstrates sustained drug release yielding promising results; suggesting both novel device and method to enhance drug activity at the eyes surface which will reduce formulation drainage.
Sujet(s)
Lentilles de contact , Cornée/effets des médicaments et des substances chimiques , Cornée/métabolisme , Nébuliseurs et vaporisateurs , Absorption oculaire/effets des médicaments et des substances chimiques , Timolol/métabolisme , Antagonistes bêta-adrénergiques/administration et posologie , Antagonistes bêta-adrénergiques/composition chimique , Antagonistes bêta-adrénergiques/métabolisme , Animaux , Bovins , Préparation de médicament , Absorption oculaire/physiologie , Timolol/administration et posologie , Timolol/composition chimiqueRÉSUMÉ
BACKGROUND: Topical use of timolol for infantile hemangiomas has recently emerged with promising results. It is unknown whether topical ß-blockers act locally or if their effect is partly due to systemic absorption. This study investigates whether topically applied timolol is absorbed and reports on the efficacy of this treatment. METHODS: We treated 40 infants with small proliferating hemangiomas with topical timolol gel 0.5% twice daily and assessed urinary excretion and serum levels in a proportion of patients. Clinical response was evaluated on a visual analog scale of standardized photographs after 1, 2, 3, and 5 months. RESULTS: Forty infants with a median age of 18 weeks (range 2-35 wks) were included; 23 (58%) had superficial and 17 (42%) mixed-type hemangiomas. The median size was 3 cm(2) (range 0.1-15 cm(2) ) and nine hemangiomas were ulcerated. The hemangiomas improved significantly during treatment, with a median increase in visual analog scale of 7 points after 5 months (p < 0.001). Urinalysis for timolol was performed in 24 patients and was positive in 20 patients (83%). In three infants, serum levels of timolol were also measured and were all positive (median 0.16 ng/mL [range 0.1-0.18 ng/mL]). No significant side effects were recorded. CONCLUSION: Topical therapy with timolol is effective for infantile hemangiomas, but systemic absorption occurs. Serum levels in our patients were low, suggesting that using timolol for small hemangiomas is safe, but caution is advised when treating ulcerated or large hemangiomas, very young infants, or concomitantly using systemic propranolol.
Sujet(s)
Antagonistes bêta-adrénergiques/administration et posologie , Hémangiome/traitement médicamenteux , Timolol/administration et posologie , Absorption physiologique , Administration par voie topique , Antagonistes bêta-adrénergiques/métabolisme , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Nouveau-né , Grossesse , Timolol/métabolismeRÉSUMÉ
Melanin binding is known to affect the distribution and elimination of ocular drugs. The purpose of this study was to evaluate if the extent of drug uptake to primary retinal pigment epithelial (RPE) cells could be estimated based on in vitro binding studies with isolated melanin and evaluate the suitability of single photon emission computed tomography/computed tomography (SPECT/CT) in studying pigment binding in vivo with pigmented and albino rats. Binding of five compounds, basic molecules timolol, chloroquine, and nadolol and acidic molecules methotrexate and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF), was studied using isolated melanin from porcine choroid-RPE at pH 5.0 and 7.4. The uptake to primary porcine RPE cells was studied with timolol, chloroquine, methotrexate, and CDCF. The cell study setting was modeled using parameters from the in vitro binding study. In vivo kinetics of 3-[I-123]-iodochloroquine was studied by the SPECT/CT method in albino and pigmented rats. All basic compounds bound to melanin at both pH values, whereas the acidic compounds bound more at pH 5.0 than at pH 7.4. The basic compounds (chloroquine, timolol) showed significant cellular uptake, unlike the acidic compounds (methotrexate, CDCF). On the basis of the modeling, melanin binding was a major factor governing the overall drug distribution to the RPE cells. Likewise, melanin binding explained distribution of 3-[I-123]-iodochloroquine in the pigmented RPE, whereas drug accumulation was not seen in the albino rat. This study demonstrates the suitability of noninvasive SPECT/CT imaging in monitoring ocular melanin binding in vivo. These studies are a useful step toward understanding the pharmacokinetic impact of melanin binding.
Sujet(s)
Mélanines/métabolisme , Épithélium pigmentaire de la rétine/métabolisme , Tomographie par émission monophotonique couplée à la tomodensitométrie/méthodes , Animaux , Cellules cultivées , Chloroquine/métabolisme , Oeil/métabolisme , Concentration en ions d'hydrogène , Radio-isotopes de l'iode , Cinétique , Méthotrexate/métabolisme , Nadolol/métabolisme , Liaison aux protéines , Rats , Suidae , Timolol/métabolismeRÉSUMÉ
The aim of this work was to assess the performance of resin as an ocular delivery system. Timolol maleate (TM) was chosen as the model drug and an ion exchange resin (IER) as the carrier. The drug-resin complex was prepared using an oscillation method and then characterized regarding particle size, zeta potential, morphology, and drug content. After in vitro drug release study and corneal permeation study were performed, in vivo studies were performed in New Zealand albino rabbits using a suspension with particles sized 4.8 ± 1.2 µm and drug loading at 43.00 ± 0.09%. The results indicate that drug released from the drug-resin ophthalmic suspension permeated the cornea and displayed a sustained-release behavior. Drug levels in the ocular tissues after administration of the drug-resin ophthalmic suspension were significantly higher than after treatment with an eye drop formulation but were lower in body tissues and in the plasma. In conclusion, resins have great potential as effective ocular drug delivery carriers to increase ocular bioavailability of timolol while simultaneously reducing systemic drug absorption.
Sujet(s)
Cornée/effets des médicaments et des substances chimiques , Préparations à action retardée/synthèse chimique , Résines échangeuses d'ions/synthèse chimique , Solutions ophtalmiques/synthèse chimique , Timolol/synthèse chimique , Antagonistes bêta-adrénergiques/administration et posologie , Antagonistes bêta-adrénergiques/synthèse chimique , Antagonistes bêta-adrénergiques/métabolisme , Animaux , Chimie pharmaceutique , Cornée/métabolisme , Préparations à action retardée/administration et posologie , Préparations à action retardée/métabolisme , Vecteurs de médicaments/administration et posologie , Vecteurs de médicaments/synthèse chimique , Vecteurs de médicaments/métabolisme , Résines échangeuses d'ions/administration et posologie , Résines échangeuses d'ions/métabolisme , Solutions ophtalmiques/administration et posologie , Solutions ophtalmiques/métabolisme , Lapins , Rats , Suspensions , Timolol/administration et posologie , Timolol/métabolismeRÉSUMÉ
A 59-year-old man presented to the emergency department with lightheadedness. He had started intranasal administration of ophthalmic timolol for the prevention of epistaxis associated with hereditary haemorrhagic telangiectasia approximately 3 weeks earlier with excellent response. His heart rate was about half its normal rate, an ECG revealed sinus bradycardia, and it was determined he had significant cardiac issues in his family history. Essentially all other tests were normal. The discontinuation of the intranasal use of timolol resolved any further episodes of lightheadedness and bradycardia. It was determined through genetic testing that he is an intermediate metaboliser of CYP2D6, the main enzyme contributing to the metabolism of timolol. This explains the development of the bradycardia after intranasal timolol use. The metabolising variants of CYP2D6 need to be considered when prescribing medications metabolised by this enzyme, so possible adverse effects can be avoided.
Sujet(s)
Antagonistes bêta-adrénergiques/effets indésirables , Bradycardie/induit chimiquement , Épistaxis/prévention et contrôle , Télangiectasie hémorragique héréditaire/complications , Timolol/effets indésirables , Administration par voie nasale , Antagonistes bêta-adrénergiques/métabolisme , Cytochrome P-450 CYP2D6/génétique , Cytochrome P-450 CYP2D6/métabolisme , Épistaxis/étiologie , Humains , Mâle , Adulte d'âge moyen , Solutions ophtalmiques , Timolol/métabolismeRÉSUMÉ
We have developed a cylindrical insert that can be inserted in the fornix for extended release of glaucoma drug timolol. The insert is prepared by incorporating timolol-loaded nanoparticles into a poly hydroxyl ethyl methacrylate (p-HEMA) matrix. A 1-mm diameter, 7.5-mm long insert with 25% (w/w) particles can release timolol for about 10 days at an average rate of about 15 µg/day, which may be therapeutically effective. The increase in particle fraction increases drug loading, but also increases the release duration. The net effect of increasing the particle fraction is a significant increase in release duration, but a decrease in daily drug release rates, in the first few weeks. The release duration increases to about 1 and 3 months on increasing the particle fraction to 50% and 75%, respectively. The average daily release rates in the first 3 weeks are 15, 9, and 3 µg/day for the inserts with 50%, 75%, and 100% (w/w) particles, respectively. The mechanism of release is hydrolysis of the ester bond that links timolol to the propoxylated glyceryl triacrylate matrix, and thus the release profiles fit a first order reaction model. The water content of the inserts decreases from 31% to almost zero on increasing the particle loading from 25% to 100%. The rate constant for the hydrolysis decreases with an increase in particle loading in the insert most likely due to the reduction in the water content. The inserts can be packaged in wet conditions and stored in a refrigerator, but the inserts will exhibit a burst release caused by release of the drug from the particles into the p-HEMA matrix during the shelf life. Also, the magnitude of drug release after the initial burst is reduced due to the storage. The burst effect could potentially be avoided by packaging the inserts in a dry state, with hydration before insertion.
Sujet(s)
Chimie pharmaceutique/méthodes , Glaucome/traitement médicamenteux , Nanoparticules/administration et posologie , Timolol/administration et posologie , Capsules , Chimie pharmaceutique/tendances , Préparations à action retardée/administration et posologie , Préparations à action retardée/composition chimique , Préparations à action retardée/métabolisme , Vecteurs de médicaments/administration et posologie , Vecteurs de médicaments/composition chimique , Vecteurs de médicaments/métabolisme , Glaucome/métabolisme , Nanoparticules/composition chimique , Taille de particule , Timolol/composition chimique , Timolol/métabolismeRÉSUMÉ
Mechanism of G protein-coupled receptor (GPCR) activation and their modulation by functionally distinct ligands remains elusive. Using the technique of amide hydrogen/deuterium exchange coupled with mass spectrometry, we examined the ligand-induced changes in conformational states and stability within the beta-2-adrenergic receptor (ß(2)AR). Differential HDX reveals ligand-specific alterations in the energy landscape of the receptor's conformational ensemble. The inverse agonists timolol and carazolol were found to be most stabilizing even compared with the antagonist alprenolol, notably in intracellular regions where G proteins are proposed to bind, while the agonist isoproterenol induced the largest degree of conformational mobility. The partial agonist clenbuterol displayed conformational effects found in both the inverse agonists and the agonist. This study highlights the regional plasticity of the receptor and characterizes unique conformations spanning the entire receptor sequence stabilized by functionally selective ligands, all of which differ from the profile for the apo receptor.
Sujet(s)
Mesure d'échange de deutérium/méthodes , Structure tertiaire des protéines , Récepteurs bêta-2 adrénergiques/composition chimique , Agonistes des récepteurs béta-2 adrénergiques/métabolisme , Antagonistes des récepteurs bêta-2 adrénergiques/métabolisme , Alprénolol/métabolisme , Sites de fixation , Clenbutérol/métabolisme , Humains , Liaison hydrogène , Ligands , Spectrométrie de masse , Membranes/métabolisme , Peptides/métabolisme , Propanolamines/métabolisme , Liaison aux protéines , Stabilité protéique , Récepteurs bêta-2 adrénergiques/métabolisme , Timolol/métabolismeRÉSUMÉ
The new beta(2) Adrenoceptor (beta(2)AR) crystal structures provide a high-resolution snapshot of receptor interactions with two particular partial inverse agonists, (-)-carazolol and timolol. However, both experimental and computational studies of GPCR structure are significantly complicated by the existence of multiple conformational states coupled to ligand type and receptor activity. Agonists and antagonists induce or stabilize distinct changes in receptor structure that mediate a range of pharmacological activities. In this work, we (1) established that the existing beta(2)AR crystallographic conformers can be extended to describe ligand/receptor interactions for additional antagonist types, (2) generated agonist-bound receptor conformations, and (3) validated these models for agonist and antagonist virtual ligand screening (VLS). Using a ligand directed refinement protocol, we derived a single agonist-bound receptor conformation that selectively retrieved a diverse set of full and partial beta(2)AR agonists in VLS trials. Additionally, the impact of extracellular loop two conformation on VLS was assessed by docking studies with rhodopsin-based beta(2)AR homology models, and loop-deleted receptor models. A general strategy for constructing and selecting agonist-bound receptor pocket conformations is presented, which may prove broadly useful in creating agonist and antagonist bound models for other GPCRs.
Sujet(s)
Agonistes des récepteurs béta-2 adrénergiques , Propanolamines/métabolisme , Récepteurs bêta-2 adrénergiques/métabolisme , Timolol/métabolisme , Antagonistes des récepteurs bêta-2 adrénergiques , Séquence d'acides aminés , Simulation numérique , Cristallographie aux rayons X , Humains , Liaison hydrogène , Bibliothèques numériques , Ligands , Modèles moléculaires , Données de séquences moléculaires , Propanolamines/composition chimique , Liaison aux protéines , Conformation des protéines , Récepteurs bêta-2 adrénergiques/composition chimique , Rhodopsine/composition chimique , Rhodopsine/métabolisme , Alignement de séquences , Timolol/composition chimiqueRÉSUMÉ
Ophthalmic timolol has been used for decades in the treatment of glaucoma and ocular hypertension, traditionally in aqueous 0.5% eye drops. Recently a timolol 0.1% hydrogel has been developed to improve systemic safety. The aim of the present study was to compare aqueous humor timolol concentrations after administration of 0.1% hydrogel and aqueous 0.5% timolol in patients scheduled for a cataract operation. The concentration in the aqueous humor was 210+/-175 ng/ml (mean+/-S.D.) 2h after administration of timolol 0.1% hydrogel and 538+/-304 ng/ml after aqueous 0.5% timolol. In the aqueous 0.5% timolol group more patients had unnecessarily high concentrations of timolol in the aqueous humor. beta(1)-receptors and beta(2)-receptors were practically 100% occupied after administration of both products. The hydrogel proved to be an excellent formulation in giving smaller inter-individual variation in penetration of timolol into the aqueous humor. Only a weak correlation was seen between corneal thickness and the aqueous humor concentration of timolol in the aqeuous 0.5% timolol group. In conclusion, in contrast to the conventional aqueous 0.5% timolol, 0.1% timolol hydrogel caused only slight inter-individual variation in timolol concentration in the aqueous humor.
Sujet(s)
Humeur aqueuse/métabolisme , /composition chimique , Véhicules pharmaceutiques/composition chimique , Timolol/administration et posologie , Timolol/pharmacocinétique , Antagonistes bêta-adrénergiques/administration et posologie , Antagonistes bêta-adrénergiques/métabolisme , Antagonistes bêta-adrénergiques/pharmacocinétique , Facteurs âges , Sujet âgé , Sujet âgé de 80 ans ou plus , Cornée/anatomie et histologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Récepteurs bêta-adrénergiques/métabolisme , Larmes/effets des médicaments et des substances chimiques , Larmes/métabolisme , Timolol/métabolismeRÉSUMÉ
In this work, different modifications of photo-cross-linked poly(propylene fumarate)/poly(N-vinyl pyrrolidone) (PPF/PNVP) matrices were studied for their effect on the release kinetics of two ophthalmic drugs. The hydrophilicity of solid PPF/PNVP matrices loaded with acetazolamide (AZ) or timolol maleate (TM) was increased by adding various amounts of poly(ethylene glycol) (PEG) or by increasing the amount of N-vinyl pyrrolidone (NVP) in the polymer mixture prior to cross-linking. The in vitro release studies that utilized high-performance liquid chromatography for quantification revealed highly accelerated drug release from the matrices with increasing contents of the hydrophilic modifier. AZ was released from matrices containing 5% PEG in 56 days, which equals approximately 25% of the release period found for the unmodified matrices. A comparable acceleration in drug release was found for TM-loaded samples modified with 5% PEG. These studies further revealed that 1% PEG is sufficient to shorten the TM release duration by one-third. A significant acceleration in drug release was also found for the samples that were fabricated from a PPF-NVP mixture with increased NVP content. Matrix water content and erosion were assessed gravimetrically. Micro-computed tomography was used to image structural changes of the release systems and shed light on the drug-release mechanism. This study showed that hydrophilic matrix modifications of PPF/PNVP matrices accelerate the drug release of two ophthalmic drugs and represent a suitable tool to adjust drug-release rates from PPF-based matrices for different therapeutic needs.
Sujet(s)
Vecteurs de médicaments/composition chimique , Systèmes de délivrance de médicaments , Fumarates/composition chimique , Solutions ophtalmiques/composition chimique , Polymères/composition chimique , Polypropylènes/composition chimique , Acétazolamide/composition chimique , Acétazolamide/métabolisme , Antihypertenseurs/composition chimique , Antihypertenseurs/métabolisme , Diurétiques/composition chimique , Diurétiques/métabolisme , Voies d'administration de substances chimiques et des médicaments , Oeil/composition chimique , Oeil/métabolisme , Fumarates/synthèse chimique , Structure moléculaire , Solutions ophtalmiques/métabolisme , Polyéthylène glycols/composition chimique , Polypropylènes/synthèse chimique , Timolol/composition chimique , Timolol/métabolismeRÉSUMÉ
Timolol has mainly been used topically for the treatment of glaucoma. It has been suggested that the drug is metabolized by cytochrome P450 CYP2D6. The matter has not, however, been extensively studied. The aim here was to tentatively identify timolol metabolites and to determine the P450-associated metabolic and interaction properties of timolol in vitro. Four metabolites were identified, the most abundant being a hydroxy metabolite, M1. The K(m) value for the formation of M1 was 23.8 microM in human liver microsomes. Metabolism of timolol with recombinant P450s and correlation analysis have confirmed the conception that the drug is metabolized principally by CYP2D6, CYP2C19 being only a minor contributor (<10%) to the intrinsic microsomal clearance. The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro K(i) value of 0.08 microM. Fluvoxamine, an inhibitor of CYP2C19, inhibited timolol metabolism to a lesser extent, confirming its minor contribution. Timolol itself did not inhibit CYP2D6-catalyzed dextromethorphan O-demethylation. Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo. In conclusion, the inhibition of timolol metabolism by quinidine should be taken into account when patients are treated with timolol. However, when plasma timolol concentrations in patients remain low (< or = 0.2 microg/l), it is suggested that such interaction is of minor clinical relevance.
Sujet(s)
Antagonistes bêta-adrénergiques/métabolisme , Cytochrome P-450 CYP2D6/métabolisme , Microsomes du foie/enzymologie , Timolol/métabolisme , Antagonistes bêta-adrénergiques/composition chimique , Aryl hydrocarbon hydroxylases/antagonistes et inhibiteurs , Aryl hydrocarbon hydroxylases/métabolisme , Biotransformation , Chromatographie en phase liquide à haute performance , Cytochrome P-450 CYP2C19 , Cytochrome P-450 CYP2D6/génétique , Inhibiteurs du cytochrome P-450 CYP2D6 , Désalkylation , Dextrométhorphane/métabolisme , Interactions médicamenteuses , Antienzymes/pharmacologie , Fluvoxamine/pharmacologie , Humains , Hydroxylation , Techniques in vitro , Cinétique , Microsomes du foie/effets des médicaments et des substances chimiques , Mixed function oxygenases/antagonistes et inhibiteurs , Mixed function oxygenases/métabolisme , Modèles biologiques , Structure moléculaire , Oxydoréduction , Quinidine/pharmacologie , Protéines recombinantes/métabolisme , Spectrométrie de masse ESI , Spectrométrie de masse en tandem , Timolol/composition chimiqueRÉSUMÉ
PURPOSE: The purpose of this study was to compare the binding affinity of bunazosin and dorzolamide to synthetic melanin relative to that of timolol. METHODS: Synthetic melanin was prepared from dopa by the action of tyrosinase. Timolol, dorzolamide, and bunazosin were incubated separately at a concentration of 10(-4) M in 2 ml of 0.066 M phosphate buffer containing 5 mg of synthetic melanin. After centrifugation, the absorbance of each free drug in the supernatant was measured at its optimum wavelength. The percentage of each drug bound to melanin was calculated directly from the change in absorbance relative to the initial value. RESULTS: The increase in the binding rates of all three drugs seemed to reach a plateau after 30 min. After incubating for 60 min, the binding rate of timolol was 22.2% +/- 4.9%, bunazosin 36.3% +/- 2.5%, and dorzolamide 8.5% +/- 1.9%. There were statistically significant differences between the binding rates of each drug. CONCLUSIONS: Under our study conditions, the order of binding affinity of these ocular hypotensive agents to synthetic melanin seems to be as follows: bunazosin>timolol>dorzolamide.
Sujet(s)
Antihypertenseurs/métabolisme , Mélanines/métabolisme , Quinazolines/métabolisme , Sulfonamides/métabolisme , Thiophènes/métabolisme , Timolol/métabolisme , Mélanines/synthèse chimique , Liaison aux protéinesRÉSUMÉ
To assess quantitatively the risks of ophthalmic beta-blocking agents for cardiovascular and respiratory adverse reactions, we analyzed the binding kinetics of beta-blocking agents to the beta-1 and beta-2 adrenoceptors. The relationship between the occupancies for beta-1 and beta-2 adrenoceptors and the effects on the exercise pulse rate or the forced expiratory volume in one second (FEV1) after topical administration of carteolol, befunolol, timolol and betaxolol was analyzed using a ternary complex model. The beta-1 and beta-2 receptor occupancies after ophthalmic administration were calculated to be quite high as well as those after oral administration. The maximum occupancies for beta-1 and beta-2 receptors after ordinary ophthalmic administration were 52% and 88% for carteolol, 52% and 61% for befunolol, 62% and 82% for timolol, and 44% and 3% for betaxolol, respectively. Concave relationships were obtained between a decrease in exercise pulse rate and the beta-1 receptor occupancy and between a decrease in FEV1 and beta-2 receptor occupancy, respectively. Nasolacrimal occlusion was estimated to decrease the exercise pulse rate and FEV1 by 65% and 50%, respectively. The beta-1 and beta-2 adrenoceptor occupancies were proved to be the most appropriate indicators for cardiac and pulmonary adverse reactions evoked by ophthalmic beta-blocking agents.
Sujet(s)
Antagonistes bêta-adrénergiques/effets indésirables , Coeur/effets des médicaments et des substances chimiques , Poumon/effets des médicaments et des substances chimiques , Récepteurs bêta-1 adrénergiques/métabolisme , Récepteurs bêta-2 adrénergiques/métabolisme , Administration par voie orale , Administration par voie topique , Antagonistes bêta-adrénergiques/métabolisme , Bétaxolol/effets indésirables , Bétaxolol/métabolisme , Maladies cardiovasculaires/induit chimiquement , Maladies cardiovasculaires/métabolisme , Cartéolol/effets indésirables , Cartéolol/métabolisme , Exercice physique , Volume expiratoire maximal par seconde/effets des médicaments et des substances chimiques , Rythme cardiaque/effets des médicaments et des substances chimiques , Humains , Solutions ophtalmiques , Propanolamines/effets indésirables , Propanolamines/métabolisme , Troubles respiratoires/induit chimiquement , Troubles respiratoires/métabolisme , Études rétrospectives , Timolol/effets indésirables , Timolol/métabolismeRÉSUMÉ
We provide the first evidence that point mutations can constitutively activate the beta(1)-adrenergic receptor (AR). Leucine 322 of the beta(1)-AR in the C-terminal portion of its third intracellular loop was replaced with seven amino acids (I, T, E, F, C, A and K) differing in their physico-chemical properties. The beta(1)-AR mutants expressed in HEK-293 cells displayed various levels of constitutive activity which could be partially inhibited by some beta-blockers. The results of this study might have interesting implications for future studies aiming at elucidating the activation process of the beta(1)-AR as well as the mechanism of action of beta-blockers.